The triple-combination therapy demonstrated the strongest effect, achieving a further statistically significant reduction in tumour volume compared to the dual RT/anti-PD-L1 therapy (P < 0.05, Figure 5C-E, G, H). Here, CD274 is linked to neoplasm.